Print page content Print
Increase text size Decrease text size
Text Size

This site is intended for U.S. animal healthcare professionals


This site is intended for U.S. animal healthcare professionals

The first monoclonal antibody (mAB) therapy for chronic canine allergic and atopic dermatitis1

The first monoclonal antibody (mAB) therapy for chronic canine allergic and atopic dermatitis1

CYTOPOINT® helps interrupt the itch cycle, allowing dogs to stop scratching so damaged skin can heal

The canine itch cycle

Canine Itch Cycle Diagram, CYTOPOINT interrupts the itch cycle
  1. EXPOSURE: Allergens enter via the skin, often due to a disrupted or dysfunctional epidermal barrier2
  2. SENSITIZATION: Allergens are detected by the immune system, priming the immune system to respond to the allergens in the future2
  3. CYTOKINE RELEASE: Exposure to allergens triggers T-cell activation and the release of itch- and inflammation-causing cytokines such as IL-312
  4. JAK ENZYME ACTIVATION: IL-31 activates peripheral nerves via the JAK-STAT pathway, resulting in transmission of the itch signal to the brain3
  5. ITCH/SCRATCH STIMULATION: The itch signal in the brain triggers scratching behavior. This, combined with cytokine-induced inflammation, further disrupts the epidermal barrier2,4
  6. EPIDERMAL DAMAGE: The weakened barrier makes the dog more vulnerable to transepidermal entry of allergens, thus restarting and perpetuating the cycle of itch2

View CYTOPOINT efficacy studies

Zoetis' extensive research into the itch cycle has resulted in two innovative and highly targeted therapies, giving veterinarians the flexibility to offer customized treatment for canine allergic and atopic dermatitis.

Visit our website to learn more about APOQUEL® (oclacitinib tablet), a daily oral tablet offering fast and safe relief of itch in dogs with allergic dermatitis and atopic dermatitis.


Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines. For more information, please see the full Prescribing Information.



We are Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2020 Zoetis Services LLC. All rights reserved.